Cytokinetics (CYTK)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$72.72-1.66%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CYTK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -36.8% |
| Our one-year growth estimate | diamond | -60.0% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 23.2 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CYTK — litigation filed
Dated 2026-08-13
Other Events. On August 13, 2026, Cytokinetics, Incorporated (the “Company”) filed a complaint in the United States District Court for the District of Delaware against Bristol-Myers Squibb Company and MyoKardia, Inc. The complaint seeks a declaratory judgment that the Company does not infringe U.S. Patent No. 12,616,697 (the “’697 patent”) and that the claims of the ’697 patent are invalid. In the complaint, the Company requests, among other things: a judgment declaring that the Company does…
Why it matters: Better cash flow shows improved management of costs and how well the company makes money.
Supportive ifCash from operations turns positive in Q2 2026.
Worry ifCash from operations remains negative in Q2 2026.
Why it matters: Good results could lead to more use of aficamten. This may help investors feel better.
Supportive ifThe ACACIA-HCM results show clear improvements in the main goals.
Worry ifThe results show no clear improvements or bad outcomes.
Why it matters: A slowdown in growth could affect Cytokinetics' results and future plans.
Worry ifSector revenue growth reported below the median of 10% in the next quarter.
Less concerning ifSector revenue growth remains above the median of 10%.
Why it matters: Submitting the NDA could create new market chances for aficamten. This could increase its use and revenue.
Supportive ifManagement confirms the NDA is submitted in Q4 2026 as planned.
Worry ifManagement delays or cancels the NDA submission. This shows possible problems with the drug's approval.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$143 on $10,000 · ±1.4% | How much price usually moves either way. |
| Bad day | $414 loss on $10,000 · 4.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,874 loss on $10,000 · 18.7% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The results will show if aficamten works for non-obstructive HCM. Good results could raise confidence in the drug's market potential.
Supportive ifThe presentation shows clear improvements in KCCQ and peak VO2 from the start.
Worry ifThe presentation shows no clear problems. There are no safety issues that could stop future approvals.
Why it matters: FDA approval would widen aficamten's label. This could boost sales and market share.
Supportive ifThe FDA approves the supplemental NDA for MAPLE-HCM by the PDUFA date of November 14, 2026.
Worry ifThe FDA rejects the sNDA or issues a complete response letter, delaying market expansion.
Why it matters: Effective cost management is key to improving financial health and cash flow.
Supportive ifOperating costs drop by at least 10% from last quarter.
Worry ifOperating costs go up or stay the same from last quarter.
Why it matters: A successful launch would expand market reach and validate the drug's demand in Europe.
Supportive ifThe launch is successful with strong prescriber and patient interest in Germany.
Worry ifLaunch fails to gain traction, with low prescriber engagement and patient uptake.
Why it matters: Higher expenses could mean ongoing cost management issues. This may impact cash flow.
Worry ifOperating costs are over $870 million for 2026.
Less concerning ifOperating costs stay at or below the $830 million to $870 million range.
Why it matters: Partnerships can increase sales and support the company's growth plans.
Supportive ifAt least one new partnership is expected to bring in over $10M.
Worry ifNo new partnerships announced in the next quarter.
Why it matters: High operating costs can mean issues with managing expenses. This can lower profits.
Worry ifOperating expenses rise more than 5% quarter over quarter in Q2.
Less concerning ifOperating expenses drop or stay the same from last quarter in Q2.
Why it matters: A lower cash burn rate shows better expense control and efficiency.
Supportive ifCash burn rate in Q2 2026 is less than $140 million.
Worry ifCash burn rate in Q2 2026 exceeds $150 million.
Why it matters: Positive results could boost confidence in aficamten's broader market potential. This trial is key for expanding its use.
Supportive ifTop results show clear gains in KCCQ and exercise performance.
Worry ifResults do not meet main goals and show no clear improvements.
Why it matters: The results will show if aficamten works for nHCM. Good results could help the market.
Supportive ifACACIA-HCM shows good results. Patients see big improvements.
Worry ifResults show no big improvements. This raises safety worries and hurts the market.
Why it matters: Growth in MYQORZO revenue shows it is doing well in the market. This helps the company's finances.
Supportive ifMYQORZO net product revenue exceeds $25 million in Q3 2026.
Worry ifMYQORZO revenue falls below $20 million in Q3 2026.
Why it matters: Strong revenue growth would show that Cytokinetics is successfully leveraging partnerships. This is key for future growth.
Supportive ifQ2 revenue grew over 20% compared to last year. This shows strong partnership performance.
Worry ifQ2 revenue growth is below 10% year over year, suggesting weak partnership impact.
Why it matters: Cytokinetics can make more money by launching in new markets. This can help them gain market share.
Supportive ifCytokinetics launches MYQORZO in at least five new markets by the first half of 2027.
Worry ifCytokinetics misses the deadline to launch MYQORZO in new markets. This is not what was expected.
Why it matters: Submitting the NDA is important for aficamten's approval in non-obstructive HCM. This can create new market chances.
Supportive ifThe company submits the supplemental NDA for aficamten for nHCM by the end of Q4 2026.
Worry ifThe company delays the NDA submission beyond Q4 2026.